Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease

International Journal of Cardiology

Volumn 57, Issue 1, 1996, Pages 69-73

  Suehiro, Tadashi ^a   Nakauchi, Yuh ^a   Yamamoto, Michiya ^a   Arii, Kaoru ^a   Itoh, Hiroyuki ^a   Hamashige, Naohisa ^b   Hashimoto, Kozo ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b Chikamori Hospital   (Japan)

Author keywords

Coronary angiography; LDL; Myocardial infarction; Oxidation

Indexed keywords

ARYLESTERASE; LOW DENSITY LIPOPROTEIN;

ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; GENETIC POLYMORPHISM; HUMAN; JAPAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR;

AGED; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CONSTRICTION, PATHOLOGIC; CORONARY ANGIOGRAPHY; CORONARY DISEASE; ESTERASES; FEMALE; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 0030589165     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(96)02779-9     Document Type: Article

References (16)

1. [1] Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993; 211: 871-879.
2. [2] Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-154.
3. [3] Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-135.
4. [4] Mackness MI, Arrol S, Abbott CA, Durrington PN. Is paraoxonase related to atherosclerosis. Chem-Biol Interact 1993; 87: 161-171.
5. [5] Furlong CE, Richter RJ, Seidel SL, Motulsky AG. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988; 43: 230-238.
6. [6] Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52: 598-608.
7. [7] Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73-76.
8. [8] Ruiz J, Blanché H, James RW, et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869-872.
9. [9] Serrato M, Marian AJ. A variant of human paraoxonase arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96: 3005-3008.
10. [10] Nakauchi Y, Suehiro T, Yamamoto M, et al. Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease. Atherosclerosis 1996; 125: 161-169.
11. [11] American Heart Association. Committee report: a reporting system on patients evaluated for coronary artery disease. Circulation 1975; 51: 7-30.
12. [12] Gensini GG. Coronary arteriography. In: Braunwald, E. editor. Heart disease. Philadelphia: WB. Saunders, 1980; 352-360.
13. [13] Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
14. [14] Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-795.
15. [15] Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 1995; 15: 89-95.
16. [16] Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 1812-1818.